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 Key concerns in kidney transplantation 
(KTx) are allograft rejection and side 
eff ects of immunosuppressive agents. Th e 
introduction of calcineurin inhibitors, 
particularly cyclosporine A (CsA), has 
greatly improved morbidity and mortal-
ity in kidney-transplanted patients, par-
ticularly as a result of more efficient 
prevention of acute rejection. However, 
the clinical use of CsA is associated with 
serious undesirable side eff ects, such as 
nephrotoxicity and arterial hyperten-
sion. 1,2 In fact, chronic allograft  neph-
ropathy is an independent risk factor for 
graft  loss and mortality aft er KTx, and 
cardiovascular complications are the 
main cause of death aft er transplanta-
tion. 2,3 Th us, extended long-term graft  
survival has not been achieved. 
 Th e recognition of these serious adverse 
effects raised interest in CsA-sparing 
schemes. Strategies to limit CsA exposure 
include avoidance, minimization, and 
withdrawal. 4 Calcineurin inhibitor avoid-
ance is associated with increased acute 
rejection rates, and these protocols have 
been discarded. CsA reduction is associ-
ated with a modest improvement in renal 
function, but the chronic allograft  neph-
ropathy increases if the exposure remains. 
Th e preferable CsA withdrawal protocols 
are early and late replacement, especially 
with sirolimus, an inhibitor of the mam-
malian target of rapamycin (mTOR). Th e 
choice depends mainly on two important 
factors: the risk of rejection and the unde-
sirable side eff ects — in particular, kidney 
injury. In general, when there is low risk 
of rejection and / or high nephrotoxicity, 
replacement might be performed earlier 
in order to protect the kidney. Early with-
drawal, before signifi cant graft  damage, 
has generally improved creatinine clear-
ance and markers of fibrosis, with 
decreased chronic allograft  lesions. Late 
CsA withdrawal has achieved variable 
results, possibly because withdrawal was 
attempted aft er the kidney damage was 
too extensive. However, there is no con-
sensus in the medical – scientifi c commu-
nity concerning the choice of combined 
protocols (early or late replacement) and 
their real benefi ts, particularly because of 
the lack of knowledge concerning the 
biomolecular mechanisms that support 
the decision. 
 Sirolimus (SRL), an inhibitor of mTOR, 
is a new option in KTx management. 
However, although the cardiorenal side 
effects of SRL are apparently less than 
those of CsA, other serious adverse eff ects, 
such as lipid abnormalities and thrombo-
cytopenia, have been reported for this 
mTOR inhibitor, and even the benefi ts 
previously reported have been recently 
discussed with regard to evidence of neph-
rotoxicity and proteinuria. 5 Even consid-
ering that substitution of CsA by SRL is 
promising, validation in long-term fol-
low-up studies in large cohorts is yet 
required in order to consistently deter-
mine whether the changes will result in a 
signifi cant improvement in patient and 
graft  survival. On the other hand, accord-
ing to some single-center studies, which 
should be further confi rmed in large ran-
domized multicenter trials, CsA with-
drawal from SRL-based therapy is 
associated with an increased risk of acute 
rejection in the short term, which remains 
one of the key concerns in transplanta-
tion. In any case, at the moment, CsA 
immunotherapy remains one of the cen-
tral pillars of solid-organ transplantation, 
and the unsolved CsA-induced kidney 
injury remains one of the main problems 
in KTx management. 
 Chronic allograft  nephropathy is a severe 
post-transplantation complication with 
a multifactorial cause. Th e article by Park 
 et al. 6 (this issue) begins with a descrip-
tion of some of the mechanisms under-
lying CsA-induced nephropathy (CIN), 
thus explaining the rationale for their 
study. Th e irreversible decline in renal 
function includes both renal vasocon-
striction and structural damage. 1,6 
CsA causes overactivity of the renin –
 angiotensin – aldosterone system (RAAS), 
thus reducing the renal blood fl ow. Angi-
otensin II promotes various actions, includ-
ing proinfl ammatory and profibrogenic 
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actions, through transforming growth 
factor-  1 (TGF-  1). Furthermore, as 
Park  et al. mention, 6 the production of 
reactive oxygen species causes cellular 
injury and promotes cell death by apop-
tosis; moreover, CsA directly upregulates 
TGF-  1 expression in tubular epithelial 
cells, independently of the hemody-
namic eff ects of the RAAS in chronic 
CIN. 1,6 Park  et al. tested the possibility 
of CIN attenuation by paricalcitol 
through inhibition of pathways depend-
ent on TGF-  1 signaling, including 
infl ammation, proliferation, and apop-
tosis 6 ( Figure 1a ). 
 Th e management of CIN includes min-
imization or withdrawal strategies (which 
must be done vigilantly because of the 
risk of acute rejection) and control of 
concomitant dyslipidemia and hyperten-
sion, particularly with the use of modula-
tors of the RAAS and calcium channel 
blockers. However, as long as the precise 
bio molecular mechanisms underlying 
the cardiorenal effects of CsA remain 
to be fully clarified, the choice of the 
most appropriate antihypertensive /
 renoprotective drug will remain a largely 
empirical decision that considers blood 
pressure control, side eff ects, and potential 
interference with immunosuppression. 
Under these conditions, the renal and car-
diovascular impairment will progress, 
thus originating one or both of two more 
serious consequences: graft  loss and death 
due to cardiorenal complications. In the 
past decades, there has been a manifest 
change in attitude toward transplantation, 
with particular attention to long-term 
kidney function and overall quality of life. 
In this context, the search for better reno-
protective post-KTx therapies should con-
tinue, and new options have been tested. 
 Paricalcitol (19-nor-1,25-hydroxyvita-
min D 2 ) is an active non-hypercalcemic 
vitamin D analog that, besides the 
expected regulation of calcium and phos-
phate levels and the control of bone 
metabolism, plays a role in protection 
from progressive renal dysfunction. 
Recent studies have indicated that vita-
min D analogs are able to reduce pro-
teinuria in chronic kidney disease patients 
apart from the benefi cial eff ects on min-
eral metabolism, further demonstrating 
an inhibitory action on the RAAS and 
anti-infl ammatory and immunomodula-
tor properties. 7,8 Th us, paricalcitol has 
been viewed as a new hope in nephropa-
thy, but the exact mechanisms underlying 
the protective action remain to be fully 
elucidated. 
 Park  et al. previously reported a reno-
protective eff ect of paricalcitol in gen-
tamicin-induced nephrotoxicity in rats 9 
and have now tested whether identical 
action could be replicated in a model of 
CsA-induced kidney injury, focusing on 
hypothetical anti-infl ammatory, antipro-
liferative, and antiapoptotic eff ects. Th e 
nephropathy model studied was charac-
terized by a functional impairment and 
structural damage, accompanied by 
markers of infl ammation. Th e authors 
proposed that the renoprotective activ-
ity of paricalcitol was due to inhibition 
of nuclear factor-  B and nitric oxide 
(NO) signaling and that this anti-
inflammatory action further causes 
reduction of TGF-  1 expression and the 
restoration of renal tubular-cell damage. 
According to the authors, on the basis 
of the data of their study, the inhibition 
of TGF-  1 pathways by paricalcitol, due 
to prevention of CsA-induced TGF-  1 
expression and TGF-  1-induced Smad-
2 / 3 and mitogen-activated protein kinase 
signaling, might be responsible for the 
attenuation of CsA-induced renal tubu-
lar-cell apoptosis and fibrosis. 6 These 
fi ndings suggest that the restoration of 
renal functional parameters and struc-
tural changes by paricalcitol may in part 
be due to the abolishment of infl amma-
tory, fi brotic, and apoptotic responses 
( Figure 1a ). Since several mechanisms 
underlying the attenuation by paricalcitol 
of gentamicin-induced kidney injury in 
rats 9 are the same as those proposed for 
the prevention of CIN, 6 paricalcitol 
might be better viewed as a general reno-
protector, and other therapeutic strate-
gies with higher specificity to CsA 
nephrotoxicity might be needed. 
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 Figure 1  |  Mechanisms of CsA-induced nephrotoxicity. Schematic summarizing ( a ) the 
hypothesis raised by Park  et al. 6 for the beneficial effect of paricalcitol, and ( b ) other potentially 
relevant pathways previously reported that might be taken into consideration and estimated. 
Plus signs represent the activated pathways in CsA-induced nephrotoxicity; the minus sign 
represents the inhibitory effect of paricalcitol according to the hypothesis of Park  et al. ; 6 and 
the question mark represents the pathways for which the paricalcitol effect must be checked. 
AD, adrenaline; Ang II, angiotensin II; ET, endothelin; iNOS, inducible nitric oxide synthase; 
MAPK, mitogen-activated protein kinase; NA, noradrenaline; NF-  B, nuclear factor-  B; NO, 
nitric oxide; O 2 
 ·  −   , superoxide; ONOO  –  , peroxynitrite; PGI2, prostacyclin; RAAS, renin – angiotensin –
 aldosterone system; SNS, sympathetic nervous system; TGF-  1, transforming growth factor-  1; 
TXA2, thromboxane A 2 . 
commentar y
Kidney International (2010) 77    1057
 Although an ample characterization of 
the model was performed, vitamin D 
levels were not addressed, which might 
be relevant when a vitamin D analog is 
used as pharmacological treatment. 
Similar confirmation should be per-
formed in KTx patients under CsA-
based immunosuppressive therapy, in 
order to estimate whether vitamin D 
suppression is a key factor for the kidney 
injury and, consequently, a feasible tar-
get for renoprotective pharmacological 
post-transplantation therapy. Further-
more, as a complement to the study by 
Park  et al. , 6 the protective role of pari-
calcitol against other relevant contribu-
tors to CIN might also be estimated, 
including: the well-accepted renal vas-
cular impairment due to increased vaso-
constrictors, such as thromboxane A 2 
and endothelin 1, and / or decreased 
vasodilators, such as prostacyclin and 
NO; oxidative stress, namely through 
inducible NO synthase production of 
NO that will react with superoxide 
(O 2  ·  −   ), thus generating peroxynitrite 
(ONOO   −   ), a deleterious reactive spe-
cies; the activity of the RAAS, particu-
larly due to angiotensin II overproduction 
and / or overactivity; and the activity of 
the sympathetic nervous system, via 
noradrenaline and adrenaline produc-
tion and reactivity ( Figure 1b ). Accord-
ing to several previous reports in 
experimental models and in humans, 
these are pivotal factors for CsA-induced 
nephrotoxicity and, thus, deserve better 
clarifi cation. 10 
 In conclusion, the effi  cacy of paricalci-
tol in the prevention and attenuation of 
CsA-induced nephrotoxicity needs to be 
confi rmed by more ample research in ani-
mal models in order for it to be further 
considered as suitable for study in pro-
spective randomized trials. At the very 
least, urologists and nephrologists need 
to be aware of the potential renoprotec-
tive eff ects of paricalcitol against CIN, 
and preclinical data, such as those 
reported by Park  et al. , 6 must be consid-
ered in the design of clinical trials in post-
transplantation CsA-induced kidney 
injury. 
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 Coronary artery calcification scoring 
(CACS) by computed tomography is a 
useful method to estimate the likelihood 
of coronary heart disease and all-cause 
mortality in the general population. In 
fact, the predictive value of CACS is sever-
alfold higher than that of the Framingham 
Risk Score 1 in patients without chronic 
kidney disease. Currently, the main value 
of CACS lies in the estimation of 
 cardiovascular events, as CACS increases 
the discriminatory capacity of models that 
use conventional risk factors. 
 In patients with chronic kidney dis-
ease (CKD), however, CACS was initially 
used to identify pathophysiologic mech-
anisms of vascular calcifi cation. Braun 
 et al. , 2 who were the first to measure 
CACS by electron beam computed tom-
ography in dialysis patients, found no 
association between calcium, phosphate, 
the calcium  × phosphate product, and 
the extent of CACS. Interestingly, they 
also registered no correlation between 
CACS and coronary angiograms. Several 
subsequent studies focused on the exces-
sive calcifi cation seen in dialysis patients, 
and the persistent conviction that 
 The risk of death in patients 
with a high coronary 
calcification score: does it 
include predialysis patients ? 
 Martin H.  Haas 1 
 High coronary artery calcification score (CACS) assessed by computed 
tomography is related to mortality in asymptomatic patients with 
normal kidney function. The predictive value of CACS is still disputed in 
patients with end-stage renal disease and is unknown in patients with 
pre-terminal renal failure. Chiu and co-workers provide evidence that 
CACS is associated with mortality also in patients with chronic kidney 
disease not yet on dialysis. 
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